 Mallinckrodt plc NYSE: MNK, a global biopharmaceutical company, today announced that the Cardiovascular and Renal Drugs Advisory Committee of the U.S. Food and Drug Administration FDA will, as expected, hold a virtual meeting to review data on terlipressin, an investigational agent being evaluated for the treatment of hepatorenal syndrome type 1 HRS-1. The company announced the FDA accepted for review its New Drug Application NDA for terlipressin in April. 